News linked to both this project and an event.
Odaily News: Blockchain project Core DAO has announced a coordinated emergency hard fork, caused by validators receiving CORE rewards exceeding the blockchain's originally scheduled issuance. Core DAO stated that the incident is under control, malicious validators can no longer continue to obtain excess rewards, and the upgrade will not roll back the network or revoke confirmed transactions.Core DAO previously stated that a small number of validators had accumulated rewards significantly higher than the protocol's set issuance, and that the incident only involved reward distribution, with user assets remaining secure. Coinbase, Bithumb, Coinone, Bitget, and LBank had restricted CORE deposits, withdrawals, or transfers.Core DAO has not yet disclosed the amount of excess CORE issued, the duration of the related activity, whether the extra tokens entered circulation, or the cause of the vulnerability, and stated that it will publish a technical post-mortem report. (Cointelegraph)
Odaily sources have revealed that OKX and Korea Investment & Securities are in discussions to each acquire about a 20% stake in Coinone. The specific investment strategy is likely structured around issuing new shares rather than selling existing ones, aiming to maximize capital inflow. This equity participation appears to be primarily a financial investment and will not alter Coinone's management control.Currently, Coinone's major shareholders include The One Group (34.30% stake), Com2uS Holdings [063080] (21.95% stake), CEO Cha Myung-hoon (19.14% stake), and Com2uS Plus (16.47% stake).Industry observers believe OKX may not limit itself to a simple financial investment in the future and could also seek to participate in management or gain substantive influence. If the acquisition is successful, this transaction would be the second time in history that a major overseas exchange has attempted to gain management control of a Korean won-based exchange, following Binance's acquisition of a stake in Streami (Gopax).